I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology Neovascular Age Related Macular Degeneration

Neovascular Age Related Macular Degeneration

nAMD is an advanced form of age-related macular degeneration, a progressive retinal disease, characterised by choroidal neovascularization (or ocular angiogenesis) and vascular leakage into the retina, resulting in rapid and severe loss of central vision. Roche is committed to the development of new treatments and treatment strategies that optimize vision outcomes to improve the lives of patients and their caregivers.

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Feb 16 / Roche and Genentech
Implementation of Optimized Surgical Steps for the PDS and the Incidence of Endophthalmitis and Associated Patient Outcomes
This presentation decribes results from a retrospective analysis which examined the impact of surgical improvements on endophthalmitis incidence and patient outcomes over time in patients receiving the Port Delivery Platform with ranibizumab (PDS) in the PDS clinical development program from 2016 to 2024. A trend for improvement in endophthalmitis incidence and patient outcomes was observed after June 2020. Key updates, increased awareness, better monitoring and management in the PDS clinical trial program have all contributed to this positive trend.
Ophthalmology Neovascular Age Related Macular Degeneration Diabetic Retinopathy Diabetic Macular Edema MACULA-SOCIETY-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 15 / Roche and Genentech
Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With nAMD or DME From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study
This presentation describes the results of an interim analysis of treatment-naïve patients (baseline to month 6) receiving faricimab▼ in the innovative real-world VOYAGER study. The global VOYAGER study investigates the real-world effectiveness, safety, treatment patterns and anatomical features affecting vision outcomes with faricimab▼ in patients with nAMD and DME on a global level. Treatment-naive eyes achieved visual gains and anatomic improvements during the follow-up period.
Ophthalmology Neovascular Age Related Macular Degeneration Diabetic Macular Edema MACULA-SOCIETY-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 15 / Roche and Genentech
Treatment Patterns, Visual Outcomes, and Safety in Eyes With nAMD and DME Treated With Faricimab▼ in the UK: 1-Year Results From the FARWIDE Study
This presentation describes results from FARWIDE nAMD and DME, a retrospective, real-world study of faricimab▼, using data from the Medisoft EMR system in the UK. Data were analyzed among treatment-naïve and previously-treated patient eyes diagnosed with nAMD or DME who started faricimab▼ after June 2022 and had at least 12 months of follow-up through July 2024. The majority of eyes had been previously treated with an anti-VEGF agent; of these most had received aflibercept 2 mg. After faricimab▼ initiation, vision improved in treatment-naïve eyes and remained stable in previously-treated eyes. Fewer injections were observed from 6 months onwards, suggesting treatment interval extension.
Ophthalmology Neovascular Age Related Macular Degeneration Diabetic Macular Edema MACULA-SOCIETY-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 15 / Roche and Genentech
Real-World Clinical Outcomes Update in Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Treated With Faricimab▼ in the US: The FARETINA Study
This presentation describes results from FARETINA nAMD and DME, a retrospective, real-world study of faricimab▼, using data from the IRIS registry in the USA. Data were analyzed among treatment-naïve and previously-treated patient eyes diagnosed with nAMD or DME who started faricimab▼ after February 2022 and had at least 12 months of follow-up through September 2024. The majority of eyes had been previously treated with an anti-VEGF agent; of these most had received aflibercept 2 mg. After faricimab▼ initiation, vision improved in treatment-naïve eyes and remained stable in previously-treated eyes. Anatomic improvement was observed in both cohorts. Fewer injections were observed from 6 months onwards, suggesting treatment interval extension.
Ophthalmology Neovascular Age Related Macular Degeneration Diabetic Macular Edema MACULA-SOCIETY-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 15 / Roche and Genentech
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
This presentation describes the week 16 (interim) results of the phase 3b/4 SALWEEN study. SALWEEN is investigating the efficacy, safety and durability of faricimab▼ in patients with polypoidal choroidal vasculopathy (PCV) from Asian countries/regions. Interim efficacy and safety results have demonstrated robust improvements in vision and anatomy, and complete closure and inactivation of polypoidal lesions in the majority of patients. Faricimab▼ was well tolerated and consistent with the known safety profile of faricimab▼.
Ophthalmology Neovascular Age Related Macular Degeneration MACULA-SOCIETY-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 15 / Roche and Genentech
Baseline and Early Treatment Response Variables Associated With Faricimab▼ Durability in Treatment-nave nAMD: TENAYA/LUCERNE Post Hoc Analyses
This presentation describes results from post hoc analyses of pooled TENAYA/LUCERNE trial data evaluating the association between rapid fluid resolution and short- and long-term faricimab▼ treatment durability in patients with nAMD. The relationship between baseline characteristics and early treatment response variables with the potential for later Q20W dosing was also evaluated.
Ophthalmology Neovascular Age Related Macular Degeneration MACULA-SOCIETY-2025
Related website
Eye on Angiopoietins
Discover how angiopoietins regulate vascular stability under normal conditions and drive vascular instability in retinal and choroidal vascular diseases.
Learn more

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.